Molecular targets for anti-angiogenic therapy

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 1, 2004, Pages 54-70

  Wary, K K ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Endothelial cells; Signaling; Tumor neovasculature; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN; FIBROBLAST GROWTH FACTOR 2; INTEGRIN;

ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANGIOPOIETINS; ANIMALS; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTEGRINS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 3843051508     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (182)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med (1971) 285(21):1182-1186.
2. Folkman J, Klagsbrun M: Angiogenic factors. Science (1987) 235(4787):442-447.
3. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 7(11):1194-1201.
4. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med (1995) 1(2):149-153.
5. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86(3):353-364.
6. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res (1995) 55(20):4575-4580.
7. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR et al: Oncogenic H-Ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA (1997) 94(3):861-866.
8. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell (2003) 3(3):219-231.
9. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 3(6):401-410.
10. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284(5422):1994-1998.
11. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature (2000) 407(6801):249-257.
12. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES et al: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood (1998) 91(10):3527-3561.
13. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 146(5):1029-1039.
14. Dvorak HF: VPF/VEGF and the angiogenic response. Semin Perinatol (2000) 24(1):75-78.
15. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 2(10):795-803.
16. Jain RK: Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol (2002) 29(6 Suppl 16):3-9.
17. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279(5349):377-380.
18. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L et al: Steps toward mapping the human vasculature by phage display. Nat Med (2002) 8(2):121-127.
19. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 296(5577):2404-2407.
20. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E: Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol (2003) 163(4):871-878.
21. Armelin HA: Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci USA (1973) 70(9):2702- 2706.
22. Gospodarowicz D, Moran J: Effect of a fibroblast growth factor, insulin, dexamethasone, and serum on the morphology of BALB/c 3T3 cells. Proc Natl Acad Sci USA (1974) 71(12):4648-4652.
23. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R: An endothelial cell growth factor from bovine hypothalamus: Identification and partial characterization. Proc Natl Acad Sci USA (1979) 76(11):5674- 5678.
24. McKeehan WL, Wang F, Kan M: The heparan sulfate-fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol (1998) 59:135-176.
25. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell (2000) 103(2):211-225.
26. Owen AJ, Pantazis P, Antoniades HN: Simian sarcoma virus-transformed cells secrete a mitogen identical to platelet-derived growth factor. Science (1984) 225(4657):54-56.
27. Collins T, Ginsburg D, Boss JM, Orkin SH, Pober JS: Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis. Nature (1985) 316(6030):748-750.
28. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y: Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med (2003) 9(5):604-613.
29. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 277(5322):55-60.
30. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning. Cell (1996) 87(7):1161-1169.
31. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D et al: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 7(5):575-583.
32. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S et al: Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 9(7):936-943.
33. Hu DE, Hori Y, Fan TP: Interleukin-8 stimulates angiogenesis in rats. Inflammation (1993) 17(2):135-143.
34. Varney ML, Olsen KJ, Mosley RL, Bucana CD, Talmadge JE, Singh RK: Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: A paracrine role of tumor-associated macrophages in tumor angiogenesis. In Vivo (2002) 16(6):471-477.
35. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T: Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 99(3):301-312.
36. An S, Zheng Y, Bleu T: Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. J Biol Chem (2000) 275(1):288-296.
37. Lee MJ, Thangada S, Paik JH, Sapkota GP, Ancellin N, Chae SS, Wu M, Morales-Ruiz M, Sessa WC, Alessi DR, Hla T: Akt-mediated phosphorylation of the G protein-coupled receptor Edg-1 is required for endothelial cell chemotaxis. Mol Cell (2001) 8(3):693-704.
38. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359(6398):843-845.
39. Shima DT, Deutsch U, D'Amore PA: Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett (1995) 370(23):203-208.
40. Levy NS, Goldberg MA, Levy AP: Sequencing of the human vascular endothelial growth factor (VEGF) 3' untranslated region (UTR): Conservation of five hypoxia-inducible RNA-protein binding sites. Biochim Biophys Acta (1997) 1352(2):167-173.
41. Claffey KP, Shih SC, Mullen A, Dziennis S, Cusick JL, Abrams KR, Lee SW, Detmar M: Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability. Mol Biol Cell (1998) 9(2):469-481.
42. Ware JA, Simons M: Angiogenesis in ischemic heart disease. Nat Med (1997) 3(2):158-164.
43. Ryan HE, Lo J, Johnson RS: HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J (1998) 17(11):3005-3015.
44. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 2(1):38-47.
45. Senger DR, Perruzzi CA, Feder J, Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 46(11):5629-5632.
46. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246(4935):1306-1309.
47. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 219(4587):983-985.
48. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK: Formation of endothelial cell networks. Nature (2000) 405(6783):139-141.
49. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380(6573):435-439.
50. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene (1991) 6(9):1677-1683.
51. Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct (2001) 26(1):25-35.
52. Petrova TV, Makinen T, Alitalo K: Signaling via vascular endothelial growth factor receptors. Exp Cell Res (1999) 253(1):117-130.
53. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med (2003) 9(6):669-676.
54. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (1995) 376(6535):62-66.
55. Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 376(6535):66-70.
56. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG: LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol (1999) 144(4):789-801.
57. Wigle JT, Oliver G: Prox1 function is required for the development of the murine lymphatic system. Cell (1999) 98(6):769-778.
58. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362(6423):841-844.
59. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 367(6463):576-579.
60. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 8(12):1369-1375.
61. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 2(10):727-739.
62. Lichtenbeld HC, Ferarra N, Jain RK, Munn LL: Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. Microvasc Res (1999) 57(3):357-362.
63. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol (2003) 30(5 Suppl 16):117-124.
64. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 349(5):427-434.
65. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E: Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer (2003) 4(4):231-236.
66. Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V et al: The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res (2002) 8(4):1242-1250.
67. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 59(20):5209-5218.
68. Ward NL, Dumont DJ: The angiopoietins and Tie2/Tek: Adding to the complexity of cardiovascular development. Semin Cell Dev Biol (2002) 13(1):19-27.
69. Thurston G: Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res (2003) 314(1):61-68.
70. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell (1996) 87(7):1171-1180.
71. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (1995) 376(6535):70-74.
72. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, Goldberg J et al: Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol (2003) 10(1):38-44.
73. Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, Huang HJ, Gunji Y, Nishikawa R, Alitalo K, Cavenee WK et al: Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci USA (2003) 100(15):8904-8909.
74. Das A, Fanslow W, Cerretti D, Warren E, Talarico N, McGuire P: Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization. Lab Invest (2003) 83(11):1637-1645.
75. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C et al: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell (2002) 3(3):411-423.
76. Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB et al: Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase Tie2. Cell (1996) 87(7):1181-1190.
77. Zadeh G, Guha A: Angiogenesis in nervous system disorders. Neurosurgery (2003) 53(6):1362-1374.
78. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G: Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res (2003) 63(12):3403-3412.
79. Tse V, Xu L, Yung YC, Santarelli JG, Juan D, Fabel K, Silverberg G, Harsh G 4th: The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture. Neurol Res (2003) 25(7):729-738.
80. White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, Sullenger BA: Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA (2003) 100(9):5028-5033.
81. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 276(5317):1423-1425.
82. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 15(2):290-298.
83. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K: Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem (1998) 273(14):8413- 8418.
84. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M: Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet (2000) 67(2):295-301.
85. Evans AL, Bell R, Brice G, Comeglio P, Lipede C, Jeffery S, Mortimer P, Sarfarazi M, Child AH: Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. J Med Genet (2003) 40(9):697-703.
86. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 16(13):3898-3911.
87. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 94(11):819-825.
88. Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, Niwa H, Miyazaki Ji J, Hirota S, Kitamura Y, Kitsukawa T et al: Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA (2002) 99(6):3657-3662.
89. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C et al: Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol (2004) 5(1):74-80.
90. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K: Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA (2002) 99(13):8868-8873.
91. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M, Burgess WH, Jaye M, Schlessinger J: Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J (1990) 9(9):2685-2692.
92. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA (1986) 83(19):7297-7301.
93. Nabel EG, Yang ZY, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ: Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature (1993) 362(6423):844-846.
94. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G: Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res (2000) 60(24):7163-7169.
95. Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H: Anti-tumor angiogenesis therapy using soluble receptors: Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther (2002) 9(8):633-640.
96. Raj PA, Marcus E, Rein R: Conformational requirements of suramin to target angiogenic growth factors. Angiogenesis (1998) 2(2):183-199.
97. Gagliardi AR, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC: Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol (1998) 41(2):117-124.
98. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, Paparelli A, Del Tacca M: Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer (1993) 68(5):932-938.
99. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA: Role of Raf in vascular protection from distinct apoptotic stimuli. Science (2003) 301(5629):94-96.
100. Rifkin DB, Moscatelli D, Gross J, Jaffe E: Proteases, angiogenesis, and invasion. Symp Fundam Cancer Res (1983) 36:187-200.
101. Moscatelli D, Rifkin DB: Membrane and matrix localization of proteinases: A common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta (1988) 948(1):67-85.
102. Woessner JF Jr: The matrix metalloproteinase family. In: Matrix Metalloproteinases. Parks WC, Mecham RP (Eds), Academic Press, San Diego, CA, USA (1998):1-14.
103. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science (2002) 295(5564):2387-2392.
104. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z: Angiogenesis: Vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol (2003) 10(2):136-141.
105. Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ et al: Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet (2001) 28(3):261-265.
106. Brown PD: Matrix metalloproteinase inhibitors. Angiogenesis (1998) 1(2):142-154.
107. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol (2001) 28(6):620-625.
108. Risau W, Lemmon V: Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol (1988) 125(2):441-450.
109. Varner JA, Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin αvβ3. Important Adv Oncol (1996):69-87.
110. Bischoff J: Cell adhesion and angiogenesis. J Clin Invest (1997) 99(3):373-376.
111. Ruoslahti E: Integrins. J Clin Invest (1991) 87(1):1-5.
112. Giancotti FG, Ruoslahti E: Integrin signaling. Science (1999) 285(5430):1028-1032.
113. Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell (2002) 110(6):673-687.
114. Risau W: Mechanisms of angiogenesis. Nature (1997) 386(6626):671-674.
115. Jain RK: Molecular regulation of vessel maturation. Nat Med (2003) 9(6):685-693.
116. Eliceiri BP, Cheresh DA: The role of αv integrins during angiogenesis. Mol Med (1998) 4(12):741-750.
117. Davis GE, Camarillo CW: An α2β1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res (1996) 224(1):39-51.
118. Davis GE, Bayless KJ, Mavila A: Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. Anat Rec (2002) 268(3):252-275.
119. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164.
120. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin αvβ3for angiogenesis. Science (1994) 264(5158):569- 571.
121. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA: Definition of two angiogenic pathways by distinct av integrins. Science (1995) 270(5241):1500-1502.
122. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA: Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA (2001) 98(1):119-124.
123. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M: Inhibition of the α-v integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer (2002) 86(5):788-795.
124. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci USA (2003) 100(8):4766-4771.
125. Vuori K, Ruoslahti E: Association of insulin receptor substrate-1 with integrins. Science (1994) 266(5190):1576-1578.
126. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F: Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J (1999) 18(4):882-892.
127. Borges E, Jan Y, Ruoslahti E: Platelet-derived growth factor receptor P and vascular endothelial growth factor receptor-2 bind to the α3 integrin through its extracellular domain. J Biol Chem (2000) 275(51):39867-39873.
128. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA: Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling. J Cell Biol (2002) 157(1):149-160.
129. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA: Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol (2003) 162(5):933-943.
130. Watt FM, Hodivala KJ: Cell adhesion. Fibronectin and integrin knockouts come unstuck. Curr Biol (1994) 4(3):270-272.
131. Bader BL, Rayburn H, Crowley D, Hynes RO: Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all av integrins. Cell (1998) 95(4):507-519.
132. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM: Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat Med (2002) 8(1):27-34.
133. Carmeliet P: Integrin indecision. Nat Med (2002) 8(1):14-16.
134. Sheppard D: In vivo functions of integrins: Lessons from null mutations in mice. Matrix Biol (2000) 19(3):203-209.
135. Cheresh DA, Stupack DG: Integrin-mediated death: An explanation of the integrin-knockout phenotype? Nat Med (2002) 8(3):193-194.
136. Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nat Med (2002) 8(9):918-921.
137. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA: Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res (2000) 6(8):3056-3061.
138. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti-αvβ3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm (2001) 16(2):125-132.
139. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. Eur J Cancer (2003) 39(7):917-926.
140. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M: Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis (2003) 20(5):413-420.
141. Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong le T, Fernandez-Metzler C, Gentile MA, Fisher JE, Hartman GD, Huff JR et al: Nonpeptide αvβ3 antagonists. 8. In vitro and in vivo evaluation of a potent αvβ3 antagonist for the prevention and treatment of osteoporosis. J Med Chem (2003) 46(22):4790-4798.
142. Tucker GC: αv Integrin inhibitors and cancer therapy. Curr Opin Investig Drugs (2003) 4(6):722-731.
143. Sun XH, Copeland NG, Jenkins NA, Baltimore D: Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol (1991) 11 (11):5603-5611.
144. Christy BA, Sanders LK, Lau LF, Copeland NG, Jenkins NA, Nathans D: An Id-related helix-loop-helix protein encoded by a growth factor-inducible gene. Proc Natl Acad Sci USA (1991) 88(5):1815-1819.
145. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R: Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 401(6754):670-677.
146. Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM: Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell (2002) 2(6):473-483.
147. de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R: Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu- dependent breast tumors. Proc Natl Acad Sci USA (2003) 100(21):12337-12342.
148. Citri A, Kochupurakkal BS, Yarden Y: The achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle (2004) 3(1):51-60.
149. Ruzinova MB, Schoer RA, Gerald W, Egan JE, Pandolfi PP, Rafii S, Manova K, Mittal V, Benezra R: Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 4(4):277-289.
150. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH Jr, Stephenson JR: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci USA (1983) 80(14):4218-4222.
151. Cleveland JL, Troppmair J, Packham G, Askew DS, Lloyd P, Gonzalez-Garcia M, Nunez G, Ihle JN, Rapp UR: sv-Raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene (1994) 9(8):2217-2226.
152. Pimentel B, Sanz C, Varela-Nieto I, Rapp UR, De Pablo F, de La Rosa EJ: c-Raf regulates cell survival and retinal ganglion cell morphogenesis during neurogenesis. J Neurosci (2000) 20(9):3254-3262.
153. Pawson T, Nash P: Protein-protein interactions define specificity in signal transduction. Genes Dev (2000) 14(9):1027-1047.
154. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A: Endothelial apoptosis in bRaf-deficient mice. Nat Genet (1997) 16(3):293-297.
155. Yokoyama C, Tanabe T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun (1989) 165(2):888-894.
156. Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA (2002) 99(21):13926-13931.
157. Warner TD, Mitchell JA: Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA (2002) 99(21):13371-13373.
158. Trifan OC, Hla T: Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med (2003) 7(3):207-222.
159. Leung WK, To KF, Go MY, Chan KK, Chan FK, Ng EK, Chung SC, Sung JJ: Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol (2003) 23(5):1317-1322.
160. Choy H, Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J Natl Cancer Inst (2003) 95(19):1440-1452.
161. Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F: The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest (2002) 32(11):838-846.
162. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res (1995) 1(12):1623-1634.
163. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res (1998) 18(3A):1485- 1500.
164. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N: Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res (1999) 59(4):856-861.
165. Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA: Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS (2003) 111 (11):1011-1018.
166. Bourdeau A, Dumont DJ, Letarte M: A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest (1999) 104(10):1343- 1351.
167. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C: Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-β receptors I and II. J Biol Chem (2002) 277(32):29197-29209.
168. Barbara NP, Wrana JL, Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem (1999) 274(2):584-594.
169. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem (2002) 277(46):43799-43808.
170. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK: Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res (2001) 7(3):524-532.
171. She X, Matsuno F, Harada N, Tsai H, Seon BK: Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-β in suppression of growth of human endothelial cells. Int J Cancer (2004) 108(2):251-257.
172. Gudmundsson GH, Magnusson KP, Chowdhary BP, Johansson M, Andersson L, Boman HG: Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: Comparative mapping of the locus for the human peptide antibiotic FALL-39. Proc Natl Acad Sci USA (1995) 92(15):7085-7089.
173. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, Goldberg AL, Simons M: Inhibition of ubiquitin-proteasome pathway-mediated IΚBα degradation by a naturally occurring antibacterial peptide. J Clin Invest (2000) 106(3):439-448.
174. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG et al: PR39, a peptide regulator of angiogenesis. Nat Med (2000) 6(1):49-55.
175. Penta K, Varner JA, Liaw L, Hidai C, Schatzman R, Quertermous T: Del1 induces integrin signaling and angiogenesis by ligation of αvβ3. J Biol Chem (1999) 274(16):11101-11109.
176. Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Quertermous T, Coleman M, Boudreau N, Varner JA: Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest (2003) 112(1):30-41.
177. Forsdyke DR: cDNA cloning of mRNAs which increase rapidly in human lymphocytes cultured with concanavalin-A and cycloheximide. Biochem Biophys Res Commun (1985) 129(3):619-625.
178. Krones-Herzig A, Adamson E, Mercola D: Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci USA (2003) 100(6):3233-3238.
179. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D: EGR1 promotes growth and survival of prostate cancer cells. Identification of novel EGR1 target genes. J Biol Chem (2003) 278(14):11802-11810.
180. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM: Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med (2003) 9(8):1026-1032.
181. Humtsoe JO, Feng S, Thakker GD, Yang J, Hong J, Wary KK: Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP. EMBO J (2003) 22(7):1539-1554.
182. Escalante-Alcalde D, Hernandez L, Le Stunff H, Maeda R, Lee HS, Jr-Gang-Cheng, Sciorra VA, Daar I, Spiegel S, Morris AJ, Stewart CL: The lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning. Development (2003) 130(19):4623-4637.